SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based ...

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in The ...

New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that OGM provided reliable and robust analytical performance with high ...

A study in The Journal of Molecular Diagnostics assessing the efficacy of optical genome mapping (OGM) in a cohort of patients with acute leukemia has demonstrated that OGM provided reliable and ...

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics ...

Join us for an installment of our Bionano In Motion webinar series as our speakers delve into immunotherapies and the emerging role of optical genome mapping (OGM) in assessing genome integrity as ...

Pregnancy loss may occur in as many as 25% of all pregnancies. Most of these losses occur in the first trimester, and about half are caused by genetic or chromosomal issues. When pregnancy loss occurs ...